Analytical Data
-
Gene name
CHMP4B
- Application
-
Alternative Names
Chromatin-modifying protein 4b
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H444
-
Expression Region
1-224aa
-
Molecular Weight
51.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHMP4B, a member of the endosomal sorting complex required for transport (ESCRT), plays a crucial role in the process of membrane trafficking and degradation of membrane proteins. Its primary function involves the sorting of ubiquitinated proteins into intraluminal vesicles of multivesicular bodies, facilitating their eventual degradation in lysosomes. Research into CHMP4B has gained significant attention due to its implications in various cellular processes, including cytokinesis, receptor downregulation, and viral budding. Dysregulation of CHMP4B has been associated with several pathological conditions, including cancer and neurodegenerative diseases, making it a potential therapeutic target. Recent studies have focused on elucidating the structural and functional dynamics of CHMP4B, exploring its interactions with other ESCRT components and examining its role in processes such as autophagy and immune response. The development of recombinant CHMP4B proteins has enabled researchers to investigate its biochemical properties and functional mechanisms in vitro, paving the way for potential clinical applications. Understanding the intricacies of CHMP4B’s functionality holds promise for developing novel strategies in disease intervention and treatment, particularly in disorders linked to cellular trafficking abnormalities.
